載入中
Artelo Biosciences, Inc. functions as a clinical-stage biopharmaceutical enterprise dedicated to discovering and advancing therapies that modulate the endocannabinoid system. The company's robust developmental portfolio encompasses several promising candidates: ART27.13, a synthetic G protein-coupled receptor agonist currently undergoing Phase 1b/2a clinical investigation for cancer-related anorexia; ART12.11, a synthetic cannabidiol cocrystal being explored for inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor with potential applications in prostate and breast cancer treatment, as well as PTSD. Further extending its research efforts, Artelo has established a collaborative partnership with Trinity College Dublin to probe ART27.13's efficacy in addressing cancer cachexia. Established in 2011, the entity initially operated under the name Reactive Medical, Inc. before rebranding as Artelo Biosciences, Inc. in April 2017. Its corporate headquarters are situated in Solana Beach, California.
收盤時
US$3.11
−US$0.15 · -4.60%
盤中時間採用ET。市場資料可能有所延遲。
Artelo Biosciences, Inc. functions as a clinical-stage biopharmaceutical enterprise dedicated to discovering and advancing therapies that modulate the endocannabinoid system. The company's robust developmental portfolio encompasses several promising candidates: ART27.13, a synthetic G protein-coupled receptor agonist currently undergoing Phase 1b/2a clinical investigation for cancer-related anorexia; ART12.11, a synthetic cannabidiol cocrystal being explored for inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor with potential applications in prostate and breast cancer treatment, as well as PTSD. Further extending its research efforts, Artelo has established a collaborative partnership with Trinity College Dublin to probe ART27.13's efficacy in addressing cancer cachexia. Established in 2011, the entity initially operated under the name Reactive Medical, Inc. before rebranding as Artelo Biosciences, Inc. in April 2017. Its corporate headquarters are situated in Solana Beach, California.
日內區間
目前US$3.11
52週區間
目前US$3.11
盤中時間採用ET。市場資料可能有所延遲。
Artelo Biosciences, Inc. functions as a clinical-stage biopharmaceutical enterprise dedicated to discovering and advancing therapies that modulate the endocannabinoid system. The company's robust developmental portfolio encompasses several promising candidates: ART27.13, a synthetic G protein-coupled receptor agonist currently undergoing Phase 1b/2a clinical investigation for cancer-related anorexia; ART12.11, a synthetic cannabidiol cocrystal being explored for inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor with potential applications in prostate and breast cancer treatment, as well as PTSD. Further extending its research efforts, Artelo has established a collaborative partnership with Trinity College Dublin to probe ART27.13's efficacy in addressing cancer cachexia. Established in 2011, the entity initially operated under the name Reactive Medical, Inc. before rebranding as Artelo Biosciences, Inc. in April 2017. Its corporate headquarters are situated in Solana Beach, California.
日內區間
目前US$3.11
52週區間
目前US$3.11
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 研究與開發 | 542.3萬 USD | 599.3萬 USD | 569.6萬 USD | 432.4萬 USD | 283.9萬 USD |
| 銷售、一般及管理費用 | 598.1萬 USD | 411.5萬 USD | 423.4萬 USD | 596.3萬 USD | 460.2萬 USD |
| 營業費用 | 1140.4萬 USD | 1010.8萬 USD | 993萬 USD | 1028.7萬 USD | 744.1萬 USD |
| 利息收入 | — | — | — | 2000 USD | 2000 USD |
| 利息支出 | 19.4萬 USD | — | — | 5000 USD | — |
| 折舊和攤銷 | 14.6萬 USD | — | — | — | — |
| 營業利益 | −1140.4萬 USD | −1010.8萬 USD | −993萬 USD | −1028.7萬 USD | −744.1萬 USD |
| 淨利 | −1287.9萬 USD | −982.6萬 USD | −928.9萬 USD | −1008.3萬 USD | −743.7萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2026年8月31日 | 1:9 | — | — |
股票分割 | 2026年3月10日 | 1:3 | — | — |
股票分割 | 2025年6月13日 | 1:6 | — | — |
股票分割 | 2022年8月10日 | 1:15 | — | — |
股票分割 | 2019年6月21日 | 1:8 | — | — |
已生效 2026年8月31日
1:9
已生效 2026年3月10日
1:3
已生效 2025年6月13日
1:6
已生效 2022年8月10日
1:15
已生效 2019年6月21日
1:8
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
